The Pediatric Hematology/Oncology faculty and research staff have active programs in clinical, clinical epidemiologic and laboratory research.
All members of the faculty participate in clinical research. Dr. Gary Kupfer currently leads Yale's participation in the Children's Oncology Group, an international pediatric oncology group that engages in cooperative group clinical trials. Dr. Howard Pearson is co-coordinator of the Connecticut State Board of Health Newborn Hemoglobinopathy Screening Program. He also participates in the New England Sickle Cell Consortium. Dr. Farzana Pashankar directs our Sickle Cell Disease Program and conducts clinical trials in childhood cancer and sickle cell anemia. Drs. Pashankar and Pearson participate in the New England Sickle Cell Consortium.
Dr. Nina Kadan-Lottick is responsible for the creation of Yale's new Clinic for Survivors of Childhood Cancer. She is leading our participation in the ALL task force, the ALL Outcomes Committee, and the Late Effects Committee within the Children's Oncology Group, as well as the Childhood Cancer Survivor Clinic initiative of the National Cancer Institute. Dr. Kadan-Lottick also conducts cancer epidemiology studies related to issues of cancer etiology and survivorship. Her current studies include (1) neurocognitive function among individuals treated for standard risk acute lymphoblastic leukemia, (2) quality of life among children enrolled on cooperative oncology therapeutic trials, and (3) bone mineral density, growth, quality of life, education, and risk of subsequent malignancies among children treated for childhood cancer.
Dr. Gary Kupfer leads our involvement in national and regional trials treating coagulopathies. He maintains an active, externally funded laboratory in ITP as well as in DNA repair, genome stability, therapeutics, and hematopoiesis.